This website is for UK Healthcare Professionals only

ANKYLOSING SPONDYLITIS

Once-daily oral treatment for your adult patients with active ankylosing spondylitis1

One dose, one tablet, once a day

Starting patients on RINVOQ

A convenient guide providing information on dosing, screening, monitoring and safety recommendations.

Dosing recommendations1

  • The recommended dose of RINVOQ is one 15-mg tablet once a day, with or without food
  • Tablets should be swallowed whole, and should not be split, crushed, or chewed
  • RINVOQ may be taken at any time of the day; patients may find it easier to take RINVOQ at the same time every day to help them remember to take it
  • Consideration should be given to discontinuing treatment in patients with ankylosing spondylitis who have shown no clinical response after 16 weeks of treatment. Some patients with initial partial response may subsequently improve with continued treatment beyond 16 weeks.

Please consult the Summary of Product Characteristics for further details regarding monitoring requirements and contraindications prior to initiating RINVOQ.

UK-UPAD-220223. Date of preparation: August 2022

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.
Adverse events should also be reported to AbbVie on GBPV@abbvie.com